178 related articles for article (PubMed ID: 2961131)
1. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
Flamm J; Spona J
Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
[TBL] [Abstract][Full Text] [Related]
2. The influence of medroxyprogesterone acetate (MPA) on hormone parameters in prostatic carcinoma patients.
Flamm J; Spona J
Int Urol Nephrol; 1988; 20(2):131-7. PubMed ID: 2968326
[TBL] [Abstract][Full Text] [Related]
3. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
4. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
Sasagawa I; Satomi S; Umeda K; Katayama T
Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
[TBL] [Abstract][Full Text] [Related]
5. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
[TBL] [Abstract][Full Text] [Related]
6. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
7. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
8. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
9. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
10. [Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors].
Balogh F; Romics I
Z Urol Nephrol; 1987 Aug; 80(8):449-53. PubMed ID: 2961162
[TBL] [Abstract][Full Text] [Related]
11. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
Tomic R; Ljungberg B; Damber JE
Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
[No Abstract] [Full Text] [Related]
12. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma.
Johansson JE; Lingårdh G
Eur Urol; 1985; 11(1):9-10. PubMed ID: 3157573
[TBL] [Abstract][Full Text] [Related]
13. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
[TBL] [Abstract][Full Text] [Related]
14. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
15. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W
Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397
[No Abstract] [Full Text] [Related]
16. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
17. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
Husslein P; Egarter C; Eppel W; Salzer H; Spona J
Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
[TBL] [Abstract][Full Text] [Related]
18. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of virginal prostatic cancer with cyproterone acetate].
Maier U
Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
[TBL] [Abstract][Full Text] [Related]
20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]